Bioactivity Comments

Peptide sequence analysis reveals that patent US6383487 [1] covers the design and uses of basiliximab. However, this patent does not provide affinity data for the interaction between the antibody and its target, IL-2, and we have been unable to find accessible data elsewhere.

Selectivity at catalytic receptors
Key to terms and symbols		Click column headers to sort
Target Sp. Type Action Value Parameter Concentration range (M) Reference Interleukin-2 receptor subunit α Hs Antibody Binding - - - ⤷